AP1860A - Aryl fused azapolycyclic compounds. - Google Patents

Aryl fused azapolycyclic compounds.

Info

Publication number
AP1860A
AP1860A APAP/P/2002/002604A AP2002002604A AP1860A AP 1860 A AP1860 A AP 1860A AP 2002002604 A AP2002002604 A AP 2002002604A AP 1860 A AP1860 A AP 1860A
Authority
AP
ARIPO
Prior art keywords
compounds
aryl fused
fused azapolycyclic
azapolycyclic compounds
aryl
Prior art date
Application number
APAP/P/2002/002604A
Other languages
English (en)
Other versions
AP2002002604A0 (en
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2002002604A0 publication Critical patent/AP2002002604A0/xx
Application granted granted Critical
Publication of AP1860A publication Critical patent/AP1860A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/2002/002604A 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds. AP1860A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
AP2002002604A0 AP2002002604A0 (en) 2002-09-30
AP1860A true AP1860A (en) 2008-07-02

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002604A AP1860A (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds.

Country Status (39)

Country Link
US (3) US6605610B1 (enExample)
EP (2) EP1619192B1 (enExample)
JP (1) JP2003524002A (enExample)
KR (1) KR100537976B1 (enExample)
CN (1) CN1263745C (enExample)
AP (1) AP1860A (enExample)
AT (2) ATE328872T1 (enExample)
AU (2) AU784081B2 (enExample)
BG (1) BG65891B1 (enExample)
BR (1) BR0108610A (enExample)
CA (1) CA2401229C (enExample)
CR (1) CR6726A (enExample)
CU (1) CU23148A3 (enExample)
CY (1) CY1105301T1 (enExample)
CZ (1) CZ303203B6 (enExample)
DE (2) DE60120366T2 (enExample)
DK (2) DK1619192T3 (enExample)
DZ (1) DZ3328A1 (enExample)
EA (1) EA005316B1 (enExample)
EE (1) EE200200475A (enExample)
ES (2) ES2263640T3 (enExample)
GE (1) GEP20053454B (enExample)
HR (1) HRP20020700A2 (enExample)
HU (1) HU229482B1 (enExample)
IL (2) IL150639A0 (enExample)
IS (1) IS2293B (enExample)
MA (1) MA26875A1 (enExample)
MX (1) MXPA02008311A (enExample)
NO (1) NO323608B1 (enExample)
NZ (1) NZ519973A (enExample)
OA (1) OA12181A (enExample)
PL (1) PL365163A1 (enExample)
PT (1) PT1259489E (enExample)
RS (1) RS51123B (enExample)
SI (1) SI1259489T1 (enExample)
SK (1) SK12042002A3 (enExample)
UA (1) UA74813C2 (enExample)
WO (1) WO2001062736A1 (enExample)
ZA (1) ZA200206768B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659114A3 (en) * 1997-12-31 2007-01-17 Pfizer Products Inc. Process for the preparation of bicyclo[3.2.1]octane fused with quinazoline derivatives
JP2004527545A (ja) * 2001-04-20 2004-09-09 ファイザー・プロダクツ・インク １，３−置換インデンおよびアリール縮合アザ多環式化合物の調製方法
JP2005507411A (ja) * 2001-10-31 2005-03-17 ファイザー・プロダクツ・インク 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
JP2005528330A (ja) * 2001-11-30 2005-09-22 ファイザー・プロダクツ・インク ５，７，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１）３，５，７，９−ペンタエンの医薬組成物
AU2002365314A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
US7309458B2 (en) * 2002-10-22 2007-12-18 Millipore Corporation Multi-sided immersion formation of composite structures and method
KR100655848B1 (ko) * 2002-11-25 2006-12-11 화이자 프로덕츠 인크. 1,3-치환된 인덴의 개선된 제조 방법
BRPI0406670A (pt) * 2003-01-15 2005-12-20 Pfizer Prod Inc Processo para a preparação de lactamas policìclicas fundidos com arila
BRPI0410219A (pt) * 2003-05-20 2006-05-09 Pfizer Prod Inc composições farmacêuticas de vareniclina
BRPI0410613A (pt) * 2003-06-04 2006-06-20 Pfizer Prod Inc preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
SI1677767T1 (sl) * 2003-10-14 2011-11-30 Xenoport Inc Kristalinična oblika analoga gama-aminomaslene kisline
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US20080275051A1 (en) * 2005-02-24 2008-11-06 Busch Frank R Preparation of High Purity Substituted Quinoxalines
KR20090007568A (ko) * 2006-04-24 2009-01-19 화이자 프로덕츠 인코포레이티드 약물 전달 장치용 비대칭 막
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
MX2010006202A (es) 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP2231644B1 (de) 2007-12-07 2014-01-15 AbbVie Deutschland GmbH & Co KG 5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8039620B2 (en) * 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2396327A1 (en) * 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
CA3161867A1 (en) * 2020-01-03 2021-07-08 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating cns disorders
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
BR0007664A (pt) * 1999-01-29 2002-05-07 Abbott Lab Derivados diazabicìclicos como ligantes receptores de acetilcolina nicotìnicos
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP2004532826A (ja) * 2001-03-19 2004-10-28 スローン−ケッタリング インスティトゥート フォー カンサー リサーチ （ｓ，ｒ，ｒ）−（−）−アクチノニンおよびそのアナログの不斉合成、ならびにそれらの使用
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Of Med. Chem, US, American Chem. Soc. WA (1979), 22(4), 455-457 *

Also Published As

Publication number Publication date
JP2003524002A (ja) 2003-08-12
PT1259489E (pt) 2006-08-31
ES2336800T3 (es) 2010-04-16
UA74813C2 (en) 2006-02-15
KR100537976B1 (ko) 2005-12-21
ATE328872T1 (de) 2006-06-15
MXPA02008311A (es) 2002-12-09
US7144882B2 (en) 2006-12-05
DK1259489T3 (da) 2006-10-09
EP1619192B1 (en) 2009-12-30
AP2002002604A0 (en) 2002-09-30
HU229482B1 (en) 2014-01-28
ATE453643T1 (de) 2010-01-15
EP1259489A1 (en) 2002-11-27
IS6459A (is) 2002-07-05
US20030130260A1 (en) 2003-07-10
AU2005234671A1 (en) 2005-12-15
HUP0204580A3 (en) 2005-04-28
EA200200716A1 (ru) 2003-02-27
KR20030005209A (ko) 2003-01-17
IL150639A (en) 2011-10-31
YU59602A (sh) 2005-06-10
CU23148A3 (es) 2006-06-29
IS2293B (is) 2007-10-15
GEP20053454B (en) 2005-02-25
CZ303203B6 (cs) 2012-05-23
PL365163A1 (en) 2004-12-27
EE200200475A (et) 2003-12-15
DE60120366T2 (de) 2007-07-05
AU2874801A (en) 2001-09-03
EA005316B1 (ru) 2004-12-30
DK1619192T3 (da) 2010-03-29
MA26875A1 (fr) 2004-12-20
CZ20022778A3 (cs) 2003-09-17
EP1259489B1 (en) 2006-06-07
CA2401229C (en) 2007-10-02
US6605610B1 (en) 2003-08-12
CN1263745C (zh) 2006-07-12
BG106908A (bg) 2003-04-30
EP1619192A2 (en) 2006-01-25
DZ3328A1 (enExample) 2001-08-30
CA2401229A1 (en) 2001-08-30
NO20024042D0 (no) 2002-08-23
AU784081B2 (en) 2006-02-02
BR0108610A (pt) 2002-11-19
CY1105301T1 (el) 2010-03-03
SK12042002A3 (sk) 2004-02-03
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
US7205300B2 (en) 2007-04-17
US20030130261A1 (en) 2003-07-10
CR6726A (es) 2003-10-28
DE60120366D1 (de) 2006-07-20
HUP0204580A2 (hu) 2003-04-28
CN1406227A (zh) 2003-03-26
BG65891B1 (bg) 2010-04-30
WO2001062736A1 (en) 2001-08-30
AU2005234671B2 (en) 2008-04-17
OA12181A (en) 2006-05-09
HK1050894A1 (en) 2003-07-11
ES2263640T3 (es) 2006-12-16
ZA200206768B (en) 2003-09-23
HRP20020700A2 (en) 2004-12-31
SI1259489T1 (sl) 2006-10-31
IL150639A0 (en) 2003-02-12
DE60140965D1 (de) 2010-02-11
RS51123B (sr) 2010-10-31
NO323608B1 (no) 2007-06-18
EP1619192A3 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
AP1860A (en) Aryl fused azapolycyclic compounds.
MY118163A (en) Aryl fused azapolycyclic compounds
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
SI1678166T1 (sl) Inhibitorji proteinske kinaze
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BG104983A (en) Aryl fused azapolycyclic compounds
MXPA01007940A (es) Derivados de azabicicloalcano y usos terapeuticos de los mismos.
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
MXPA06000892A (es) Compuestos azapoliciclicos arilo fusionados.
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
AU2001230180A1 (en) Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
MXPA04003688A (es) Compuestos azapoliciclicos condensados con arilo.
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma